Cargando…

Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD

OBJECTIVE: In non-alcoholic fatty liver disease (NAFLD), fibrosis determines the risk of liver complications. Non-invasive tests (NITs) such as FIB-4, NAFLD Fibrosis Score (NFS) and Hepamet, have been proposed as a tool to triage NAFLD patients in primary care (PC). These NITs include AST±ALT in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Karaghouli, Mustafa, Fuentes, Sonia, Davyduke, Tracy, Ma, Mang, Abraldes, Juan G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739069/ https://www.ncbi.nlm.nih.gov/pubmed/34992072 http://dx.doi.org/10.1136/bmjgast-2021-000798

Ejemplares similares

Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care
por: Davyduke, Tracy, et al.
Publicado: (2019)

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
por: Mózes, Ferenc Emil, et al.
Publicado: (2022)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis
por: Sung, Shuen, et al.
Publicado: (2021)

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
por: Montagner, Alexandra, et al.
Publicado: (2016)

Association between metabolic syndrome and liver histology among NAFLD patients without diabetes
por: Kanwar, Pushpjeet, et al.
Publicado: (2016)

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
por: Baselli, Guido Alessandro, et al.
Publicado: (2020)

NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression
por: Latif, Muhammad Umair, et al.
Publicado: (2022)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018
por: Liu, Jie, et al.
Publicado: (2022)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

Relevance of vitamin D on NAFLD and liver fibrosis detected by vibration controlled transient elastography in US adults: a cross-sectional analysis of NHANES 2017–2018
por: Ji, Yuan, et al.
Publicado: (2023)

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index
por: Liu, Ta-Wei, et al.
Publicado: (2020)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis
por: Salhab, Ahmad, et al.
Publicado: (2022)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

In silico and in vivo demonstration of the regulatory mechanism of Qi-Ge decoction in treating NAFLD
por: Peng, Chong, et al.
Publicado: (2023)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells
por: Dai, Zhen, et al.
Publicado: (2020)

Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
por: Theel, Willy B, et al.
Publicado: (2023)

Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests
por: Rhodes, Freya Alison, et al.
Publicado: (2021)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
por: Rao, Jianhua, et al.
Publicado: (2022)

Nicotinamide riboside exerts protective effect against aging-induced NAFLD-like hepatic dysfunction in mice
por: Han, Xue, et al.
Publicado: (2019)

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
por: Ikenaga, Naoki, et al.
Publicado: (2017)

Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
por: Jarvis, Helen, et al.
Publicado: (2022)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas
por: Govaere, Olivier, et al.
Publicado: (2014)

Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol
por: Brindley, James Hallimond, et al.
Publicado: (2023)

Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study
por: Wang, Kun, et al.
Publicado: (2019)

Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort
por: Luo, Laihui, et al.
Publicado: (2023)

Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma
por: Cai, Jiabin, et al.
Publicado: (2019)

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus
por: Llibre, Alba, et al.
Publicado: (2018)

Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study
por: Sun, Dan-Qin, et al.
Publicado: (2016)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
por: Haigh, Laura, et al.
Publicado: (2021)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aub1c1rmcveoqvr64bg2lb86vi